assay standardization comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-07-07. Numbers and descriptions here follow the published literature rather than marketing material.
Insulin-like growth factor 1 is produced largely in the liver in response to growth hormone signaling. Its concentration shifts over days rather than minutes, which makes it practical for tracking changes across a study period. Interpretation still depends on age, nutritional status, and concurrent illness, all of which independently affect the marker. Reference ranges are therefore stratified, and comparisons are usually made within an individual over time rather than against a single population threshold.
Assays for these markers differ in calibration and antibody specificity, so results from different platforms are not always interchangeable. Reported values can shift when a laboratory changes method, even without any biological change. Studies that span long periods or multiple sites often need cross-validation of assays. This methodological variability is a recognized limitation when comparing findings across published reports, and it remains a topic of ongoing standardization work.
Once reconstituted, the peptide is handled as a solution and is less stable than the lyophilized powder. Aqueous solutions are commonly kept cold and used within a defined period. Buffer composition and pH influence degradation rates, with extremes of acidity or alkalinity accelerating hydrolysis. Preservatives may be added in multi-dose formats to limit microbial growth. Freezing and thawing of solutions is generally avoided because it can cause precipitation or loss of activity.
Identity and purity are assessed by reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass and detects chemical modifications. Peptide mapping and amino acid analysis can verify sequence integrity. Water content is measured by Karl Fischer titration, and residual solvents may be checked by gas chromatography. These methods together support batch-to-batch consistency and routine quality control.
| Property | Value | Notes |
|---|---|---|
| Primary marker | Insulin-like growth factor 1 | Slow-changing integrated indicator of axis activity |
| Secondary marker | Growth hormone | Pulsatile; requires repeated or timed sampling |
| Typical analytical method | Immunoassay | Antibody-based quantification in serum |
| Common sample matrix | Serum | Collected under standardized conditions |
| Key interpretation factor | Age-stratified reference ranges | Baseline marker concentrations shift with age |
==== Criticism ==== David Handelsman has criticized terminology and understanding surrounding AAS in many publications. According to Handelsman, the pharmaceutical industry attempted to dissociate the so-called "androgenic" and "anabolic" effects of AAS in the mid-20th-century in order to create non-masculinizing anabolic agents that would be more suitable for use in women and children. However, this effort was unsuccessful and was abandoned by the 1970s. This was related to the subsequent discovery of a single androgen receptor (AR) mediating the effects of AAS in both muscle and reproductive tissue. In addition, it was related to misinterpretation of flawed animal androgen bioassays that had been employed to distinguish between androgenic or virilizing effects and anabolic or myotrophic effects (i.e., the Hershberger assay involving the unrepresentative levator ani muscle). In actuality, all AAS have essentially similar AR-mediated effects, even if some AAS may vary in potency in certain tissues like skin, hair follicles, and prostate gland based on their susceptibility to 5α-reduction (and associated metabolic amplification, inactivation, or lack thereof). Per Handelsman, the terms "anabolic steroid" and "anabolic–androgenic steroid" are obsolete, meaningless, and falsely distinguish these agents from androgens when there is no physiological basis for such distinction. It has also been noted that the use and distinction of the concepts "anabolic" and "androgenic", as well as the term "anabolic–androgenic steroid", are oxymoronic.
== Honors and awards == 1971 ACS Award in Chemical Instrumentation 1981 ACS Award in Analytical Chemistry 1984 William H. Nichols Medal 1985 Oesper Award 1985 J. J. Thomson Gold Medal by International Mass Spectrometry Society 1987 Pittsburgh Analytical Chemistry Award 1989 Field and Franklin Award for Mass Spectrometry 1989 University of Naples Gold Medal 1992 Robert Boyle Gold Medal by the Royal Society of Chemistry 1996 Chemical Pioneer Award from the American Institute of Chemists 1997 Bijvoet Medal of the Bijvoet Center for Biomolecular Research. 1999 J. Heyrovsky Medal by the Czech Academy of Sciences 2000 G. Natta Gold Medal by Italian Chemical Society 2001 Torbern Bergman Medal by the Swedish Chemical Society 2003 John B. Fenn Distinguished Contribution in Mass Spectrometry by the American Society for Mass Spectrometry (ASMS) 2004 Lavoisier Medal by the French Chemical Society 2006 Pehr Edman Award by the International Association for Protein Structure 2015 Nakanishi Prize from the American Chemical Society 2019 American Chemical Society designated a National Historic Chemical Landmark in Midland, MI for the demonstration of the first operating GC-MS by Fred McLafferty and Roland Gohlke.
===== Phase I ===== Phenyl-hydroxy bromazolam, 4-hydroxy bromazolam, α-hydroxy bromazolam, and α-4-dihydroxy bromazolam. The formation of phenyl-hydroxy bromazolam was catalysed by CYP2B6, CYP2C19, and CYP3A4. 4-hydroxy bromazolam, as well as α-hydroxy bromazolam, were formed by CYP2B6, CYP2C19, CYP3A4, and CYP3A5. Additionally, CYP2C9 was found to catalyse the formation of α-hydroxy bromazolam as well. α-4-dihydroxy bromazolam was only found in incubations with CYP3A4.
== Career == Eke's clinical and research career focuses on the intersection of maternal fetal medicine and pharmacologic research. He serves as the protocol chair for the International Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT) 2041, a phase I/II clinical trial evaluating the pharmacokinetics and safety of glecaprevir/pibrentasvir initiated during pregnancy among women with hepatitis C, including women co-infected with HIV. He is also involved in longitudinal cohort studies examining cardiovascular and metabolic outcomes in pregnant and postpartum women. His global health work includes contributions to Supporting, Mobilizing, and Accelerating Research for Tuberculosis Elimination (SMART4TB), a tuberculosis research initiative that integrates detection, prevention, and treatment strategies to reduce the burden of TB in high-risk settings. His broader research interests include optimizing drug safety and dosing in pregnancy and lactation, particularly in contexts such as preterm birth, HIV, tuberculosis, sickle cell disease, hypertensive disorders of pregnancy, and opioid use in pregnancy.
Sources: en.wikipedia.org
Venus was of great interest in the field of planetary science due to its thick and opaque atmosphere, the atmospheres of other planets being a novel area of research at the time. In 1961 the Venera Programme was initiated by the Soviet Union, with the launch of Venera 1. The programme would go on to mark many firsts in the exploration of another planet. Despite the later successes however, Venera 1 and Venera 2, intended to flyby Venus, resulted in failure due to losses of contact. NASA would then initiate the Mariner program with the launch of Mariner 1 and Mariner 2. Mariner 1 failed shortly after launch, however Mariner 2 would become the first man-made object to flyby another planet in December 1962 when the probe passed by Venus. Later in 1965/66, Venera 3, marked the first time a man-made object made contact with another planet after it impacted Venus on March 1, 1966, despite operational difficulties resulting in loss of contact with the craft. In 1967, Mariner 5 flew by Venus and conducted atmospheric analysis.
Pakistan was among the first nations to establish formal diplomatic ties with China, forging a strong relationship since China's 1962 conflict with India, culminating in a special bond. During the 1970s, Pakistan acted as an intermediary in U.S.-China rapprochement, facilitating US President Richard Nixon's historic visit to China. Despite changes in Pakistani governance and regional/global dynamics, China's influence in Pakistan remains paramount. In reciprocation, China stands as Pakistan's largest trading partner, with substantial investment in Pakistani infrastructure, notably the Gwadar port. In 2015 alone, they inked 51 agreements and Memorandums of Understanding (MoUs) for cooperative efforts. Both nations signed a Free Trade Agreement in 2006, with China making its largest investment in Pakistan's history through CPEC. Pakistan acts as China's liaison to the Muslim world, and both nations support each other on sensitive issues like Kashmir, Taiwan, Xinjiang, and more.
=== Special precautions === Benzodiazepines require special precaution if used in the elderly, during pregnancy, in children, in alcohol- or drug-dependent individuals, and in individuals with comorbid psychiatric disorders. Impairment of driving skills with a resultant increased risk of road traffic accidents is probably the most important adverse effect. This side-effect is not unique to flunitrazepam but also occurs with other hypnotic drugs. Flunitrazepam seems to have a particularly high risk of road traffic accidents compared to other hypnotic drugs. Extreme caution should be exercised by drivers after taking flunitrazepam.
Sources: en.wikipedia.org
It varies slowly and reflects cumulative axis activity rather than momentary secretion. Growth hormone is released in pulses affected by sleep, stress, and meals, making single readings hard to interpret. The slower marker gives a more stable picture across a study period.
Assay calibration and antibody specificity differ between platforms, so identical samples can yield different numbers. A method change within one laboratory can shift results without any biological change. Cross-validation is often needed for multi-site work.
They capture only one moment in a pulsatile pattern and are strongly influenced by recent activity and meals. Repeated sampling or overnight profiles provide a more representative view. Provocative testing is an alternative when a dynamic response is of interest.
Refrigeration between 2 and 8 degrees Celsius is typical, with protection from moisture and light. Dry, sealed containers help maintain stability over the labeled shelf life. Temperature cycling is usually minimized.